Karen White

Karen White was a former Purdue sales representative whose wrongful-termination lawsuit became one of the first courtroom tests of claims that the company’s OxyContin marketing crossed legal boundaries. She argued that Purdue fired her for refusing to promote the drug to doctors she believed were illegally overprescribing it. The jury ultimately ruled for Purdue, a result that disappointed parents who had hoped her case would make the company answer for the consequences of its sales practices.

Identity and Background

White worked for Purdue in Florida and was thirty-six when her case went to trial. Tall and trim, she had initially supported OxyContin’s painkilling promise. Her confidence in pain relief was shaped in part by witnessing her mother’s painful, premature death from cancer. That background made her later conflict with Purdue more than a dispute over sales targets: she was not rejecting the value of pain treatment, but objecting to the way she believed the drug was being promoted.

Purdue said it dismissed White in 2002 for paperwork irregularities, poor communication skills, and declining sales. White’s legal filing offered a different account: she maintained that she had been fired because she would not sell OxyContin to doctors who were illegally prescribing it in excessive amounts. The disagreement therefore turned on competing explanations for the same employment decision, as well as on whether the marketing practices she challenged could be shown to violate the law.

The Allegations Against Purdue

White argued that Purdue expected her to take part in aggressive OxyContin promotion that, in her view, crossed legal lines. Her attorney identified two doctors she had been urged to visit who were widely known for overprescribing. Both later lost their medical licenses for poor prescribing practices. These examples gave the case concrete stakes: White’s claim was not simply that she disliked a sales strategy, but that she had been pressed to promote a powerful pain medication to prescribers whose conduct raised serious concerns.

The wider circumstances in her Florida territory lent urgency to those allegations. Prescription-drug abuse had become widespread there, and an opioid-addicted veterinarian in Orange County had recently been caught using pet owners’ names to forge more than a thousand OxyContin prescriptions. The episode was not presented as proof of White’s allegations against Purdue, but it showed the extent to which OxyContin prescriptions could be diverted and abused in the environment where she had worked.

White sought $138,000 for lost wages and $690,000 for emotional pain. She had been depressed and anxious since her dismissal and had never previously been fired. The case thus joined a personal employment dispute to the broader question of whether a company’s sales practices could be held legally responsible for encouraging unsafe prescribing.

The Trial and Its Supporters

White’s civil trial took place in a Tampa federal courtroom in 2005. It was the first case against Purdue to advance beyond summary judgment. Ed Bisch drove twelve hours from Philadelphia to sit beside Lee Nuss during the proceedings. Their presence reflected the hopes of parents and advocates who believed that White’s account might establish that Purdue’s marketing had crossed a legal line and help bring public attention to OxyContin’s dangers.

Purdue’s legal team greatly outnumbered White’s. Bisch counted ten lawyers on the company’s side, besides staff, while White had one attorney. Her lawyer estimated that Purdue spent $500,000 defending the case; a company spokesman declined to confirm that figure. The imbalance gave the trial an institutional dimension: White’s allegations were heard in court against a corporation able to mount a substantial defense, while grieving families watched for a legal judgment they hoped might validate their concerns.

The case had become a focus for Relatives Against Purdue Pharma, whose members hoped White’s suit would demonstrate that Purdue’s marketing had violated the law. Barbara Van Rooyan later described the group’s expectations as exceptionally high. Their support connected White’s individual employment claim to a wider effort to challenge the company, but the parents’ hopes could not substitute for evidence meeting the court’s legal requirements.

Verdict and Significance

The jury found in Purdue’s favor. Purdue’s lawyer characterized the dispute as White’s personal disagreement with promoting the drug in a way the company considered legal. White believed that calling on doctors who improperly prescribed OxyContin was unlawful, but her lawyer did not prove that Purdue’s sales strategies themselves were illegal. At Purdue’s request, a highly critical 2003 Government Accountability Office study of the company’s marketing practices was ruled inadmissible, removing that report from the evidence the jury could consider.

The verdict did not resolve the wider allegations about OxyContin marketing; it established that White had not proved her particular claim under the evidence admitted at trial. The distinction between believing a practice was wrong and proving its illegality became central to the case. Legal scholar Richard Ausness described the difficulty of winning civil suits against Purdue, including the advantage conferred by the company’s substantial defense resources. For White and the parents who supported her, the judgment was a sharp reversal: a case that had seemed capable of exposing corporate conduct ended without a finding that the sales strategy broke the law.

Lee Nuss called Bisch after the verdict, telling him they had believed they were accomplishing something only to find that no one would act. Her reaction captured the emotional and political consequence of the loss for the families who had invested hope in White’s case. The book places the trial within the first decade of OxyContin’s existence, when the legal system could not prove that the drug’s makers had broken the law. White’s lawsuit therefore matters both for what she alleged and for what the jury’s decision left unresolved: the distance between serious public concern about marketing and the narrower question a civil court could decide on admissible proof.